Target family: M2: Angiotensin-converting enzymes (ACE and ACE2) (type: enzyme)
Target: Angiotensin-converting enzyme

Ligand: imidapril (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Primary target: yes
Median affinity:  -

Ligand: lisinopril (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1987)
Primary target: yes
Median affinity: 9.399999618530273 pKi
Reference (Journal): Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I.
Published in: Mol Pharmacol

Ligand: lisinopril-tryptophan (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.180000305175781 pIC50
Reference (Journal): Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril.
Published in: Biochem J

Ligand: moexipril (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1995)
Primary target: yes
Median affinity:  -

Ligand: moexiprilat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Median affinity: 8.2 pIC50
Reference (Journal): Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride.
Published in: Arzneimittelforschung

Ligand: perindopril (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1993)
Primary target: yes
Median affinity:  -

Ligand: perindoprilat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1993)
Primary target: yes
Median affinity: 9 pIC50
Reference (Journal): Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE.
Published in: Eur J Pharmacol

Ligand: quinapril (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1991)
Primary target: no
Median affinity: 8.100000381469727 pIC50
Reference (Journal): CI-906 and CI-907: new orally active nonsulfhydryl angiotensin-converting enzyme inhibitors.
Published in: Fed Proc

Ligand: quinaprilat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1991)
Primary target: yes
Median affinity: 8.5 pIC50
Reference (Journal): Molecular and crystal structures of MDL27,467A hydrochloride and quinapril hydrochloride, two ester derivatives of potent angiotensin converting enzyme inhibitors.
Published in: J Med Chem

Ligand: ramipril (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1991)
Primary target: yes
Median affinity: 7.599999904632568 pIC50
Reference (Journal): 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S) -2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498)--a new and highly effective angiotensin I converting enzyme inhibitor.
Published in: Arzneimittelforschung

Ligand: ramiprilat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1991)
Primary target: yes
Median affinity: 8.399999618530273 pIC50
Reference (Journal): 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S) -2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498)--a new and highly effective angiotensin I converting enzyme inhibitor.
Published in: Arzneimittelforschung

Ligand: RXP-407 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.149999618530273 pIC50
Reference (Journal): New ketomethylene inhibitor analogues: synthesis and assessment of structural determinants for N-domain selective inhibition of angiotensin-converting enzyme.
Published in: Biol Chem

Ligand: spirapril (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1994)
Primary target: yes
Median affinity:  -

Ligand: spiraprilat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1994)
Primary target: yes
Median affinity: 9.100000381469727 pIC50
Reference (Journal): Angiotensin converting enzyme inhibitors: spirapril and related compounds.
Published in: J Med Chem